Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Viatris Inc. | Glatiramer Acetate Depot | Relapsing forms of multiple sclerosis (RMS) | Phase 2a | Ongoing | Subcutaneous | Neurology |
| Vigil Neuroscience Inc. | VG-3927 | Alzheimer's disease | Phase 2 | Trial Planned | Oral | Neurology |
| Vigil Neuroscience Inc. | iluzanebart (VGL101) - (IGNITE) | Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) | Phase 2 | Trial Discontinued | intravenous | Neurology |
| Vigil Neuroscience Inc. | VGL101 - (ILLUMINATE) | Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) | Phase 2 | Ongoing | Intravenous | Neurology |
| Viking Therapeutics Inc. | VK2735 - (VANQUISH-2) | Type 2 diabetes in patients who have obesity or are overweight | Phase 3 | Ongoing | Subcutaneous | Endocrinology |
| Viking Therapeutics Inc. | VK2735 - (VANQUISH-1) | Type 2 diabetes | Phase 3 | Enrollment Conclusion | Subcutaneous | Endocrinology |
| Viking Therapeutics Inc. | VK2735 | Metabolic and endocrine disorders (GLP-1) | Phase 3 | Trial Planned | Subcutaneous | Endocrinology |
| Viking Therapeutics Inc. | VK2809 - (VOYAGE) | Non-alcoholic steatohepatitis (NASH) and fibrosis | Phase 2b | Data Released | oral | Gastroenterology |
